PharmacyCodes



Tiamcinolonum [Inn-Latin] en es it fr

Categorie

Tiamcinolonum [Inn-Latin] Les marques, Tiamcinolonum [Inn-Latin] Analogs

Tiamcinolonum [Inn-Latin] Les marques melange

  • Aristoform R Crm 0.1% (Clioquinol + Triamcinolone Acetonide)
  • Derma-4 Ont (Neomycin Sulfate + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
  • Kenacomb Cream (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
  • Kenacomb Mild Cream (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
  • Kenacomb Mild Ointment (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
  • Kenacomb Ointment (Gramicidin + Neomycin Sulfate + Nystatin + Triamcinolone Acetonide)
  • Kenacomb Ont (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
  • Mecomb Crm 0.1% (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
  • Oribiotic Ointment (Bacitracin + Lidocaine + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
  • Panolog Cream (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
  • Panolog Ointment (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
  • Ratio-Triacomb Regular Cream (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
  • Solvaderm Ointment (Neomycin (Neomycin Sulfate) + Nystatin + Thiostrepton (Antibiotic of a Streptomyces Species) + Triamcinolone Acetonide)
  • Theraderm Cream (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
  • Viaderm Kc Crm (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)
  • Viaderm Kc Ont (Gramicidin + Neomycin (Neomycin Sulfate) + Nystatin + Triamcinolone Acetonide)

    • Tiamcinolonum [Inn-Latin] Formule chimique

    C21H27FO6

    Tiamcinolonum [Inn-Latin] RX lien

    http://www.rxlist.com/cgi/generic/triamaer.htm

    Tiamcinolonum [Inn-Latin] FDA fiche

    Tiamcinolonum_[Inn-Latin] FDA

    Tiamcinolonum [Inn-Latin] msds (fiche de securite des materiaux)

    Tiamcinolonum_[Inn-Latin] MSDS

    Tiamcinolonum [Inn-Latin] Synthese de reference

    Fried et al., J. Am. Chem .. Soc. 80, 2338 (1958)

    Tiamcinolonum [Inn-Latin] Poids moleculaire

    394.434 g/mol

    Tiamcinolonum [Inn-Latin] Point de fusion

    274 - 278 (dec) oC

    Tiamcinolonum [Inn-Latin] H2O Solubilite

    80 mg / L

    Tiamcinolonum [Inn-Latin] Etat

    Solid

    Tiamcinolonum [Inn-Latin] LogP

    0.329

    Tiamcinolonum [Inn-Latin] Formes pharmaceutiques

    Crème, liquide, doseur (aérosol); Pommade; Coller; Suspension; Sirop; Tablet

    Tiamcinolonum [Inn-Latin] Indication

    Pour le traitement de la rhinite allergique perannuelle et saisonnière.

    Tiamcinolonum [Inn-Latin] Pharmacologie

    Triamcinolone et ses dérivés sont des glucocorticoïdes synthétiques qui sont utilisés pour leurs propriétés anti-inflammatoires ou immunosuppresseurs.

    Tiamcinolonum [Inn-Latin] Absorption

    Absorption rapide après une administration orale

    Tiamcinolonum [Inn-Latin] Toxicite

    DL50 => 500mg/kg (chez le rat)

    Tiamcinolonum [Inn-Latin] Information pour les patients

    Patients being treated with Azmacort Inhalation Aerosol should receive the following information and instructions. This information is intended to aid them in the safe and effective use of this medication. It is not a complete disclosure of all possible adverse or intended effects.

    Patients should use Azmacort Inhalation Aerosol at regular intervals as directed. Results of clinical trials indicate that significant improvement in asthma may occur by 1 week, but maximum benefit may not be achieved for 2 weeks or more. The patient should not increase the prescribed dosage but should contact the physician if symptoms do not improve or if the condition worsens.

    In clinical studies and post-marketing experience with Azmacort Inhalation Aerosol, local infections of the oropharynx with Candida albicans have occurred. When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while remaining on treatment with Azmacort Inhalation Aerosol. However, at times therapy with Azmacort Inhalation Aerosol may need to be interrupted.

    Patients should be instructed to track their use of Azmacort Inhalation Aerosol and to dispose of the canister after 240 actuations since reliable dose delivery cannot be assured after 240 doses.

    Patients who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles and if exposed, to obtain medical advice.

    Tiamcinolonum [Inn-Latin] Organismes affectes

    Les humains et autres mammifères